This final rule increases access to treatment with buprenorphine and buprenorphine/naloxone, allows eligible practitioners to request approval to treat up to 275 patients, and includes requirements to minimize the risk that medications provided for treatment will be misused or diverted. This rule is effective August 8, 2016. (Source: Federal Register updates via the Rural Assistance Center)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
